Research & Development
Bacterial Infections: Page 2
Sequencing test spots dangerous infections early in kids with cancer
The prospective study of 47 patients evaluated the sensitivity and specificity of the plasma microbial cell-free DNA sequencing (mcfDNA-seq) Karius test for identifying bloodstream infections three days prior to symptoms. The subjects were younger than 25 with relapsed or refractory leukemia treated at St. Jude Children's Research Hospital in Memphis, TN.
December 19, 2019
ATS, IDSA revamp pneumonia testing guidance
The new recommendations apply to the diagnosis and treatment of community-acquired pneumonia, from the time of signs and symptoms through treatment with antibiotics and follow-up chest imaging. They were published by a multidisciplinary team, including Dr. Joshua Metlay, PhD, chief of internal medicine at Massachusetts General Hospital (American Journal of Respiratory and Critical Care Medicine, October 1, 2019, Vol. 200:7, pp. e45-e65).
October 2, 2019
T2 Biosystems advances new tests through BARDA funding
The agreement with BARDA, which is part of the preparedness and response arm of the Department of Health and Human Services, will cover the development of three new direct-from-blood panels, according to the company. One panel will detect biothreat pathogens, including Bacillus anthracis and Francisella tularensis. The second is a comprehensive panel for detecting 99% of bloodborne bacterial infections by means of more than 30 reported results, including pan-Gram positive and pan-Gram negative results.
September 11, 2019
T2 Biosystems wins Medicare payment approval
As of October 1, 2019, U.S. hospitals treating Medicare inpatients with sepsis will now be eligible for a maximum NTAP amount of $97.50 -- 65% of the list price for one test -- for the T2Bacteria panel in addition to the appropriate sepsis diagnosis-related group (MS-DRG) reimbursement that hospitals receive under the Medicare hospital inpatient prospective payment system (IPPS), according to T2. The T2Bacteria panel is designed to detect sepsis-causing bacterial pathogens in the bloodstream in three to five hours without a blood culture.
August 6, 2019
GlaxoSmithKline recruits SpeeDx for antibiotics trials
SpeeDx markets in vitro testing products internationally that are aimed at minimizing the spread of treatment-resistant infections. Such products include ResistancePlus GC for Neisseria gonorrhoeae bacteria, which recently received the breakthrough device designation from the U.S. Food and Drug Administration (FDA), and ResistancePlus MG for detecting the emerging sexually transmitted infection Mycoplasma genitalium (Mgen). In a statement, the company said that it will use its existing molecular diagnostic tests as well as custom products to assist GlaxoSmithKline in ongoing trials and new product development.
June 23, 2019
Labs gear up to diagnose novel fungal infection
In the past few years, more than 600 cases of an emerging fungal infection called Candida auris have been identified in 12 U.S. states, according to the CDC.
April 14, 2019
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
C2N Diagnostics launching next-generation blood test for Alzheimer's disease detection
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Page 2 of 2